Annual report
6960.TEDINET S100TU7S
Period2023-04-01 → 2024-03-31
Filed2024-06-27
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥140.3bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥134.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥132.1bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥146.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥133.4bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥26.5bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥24.1bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥27.0bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥25.1bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥23.4bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥20.3bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥13.6bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥27.0bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥25.2bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥18.7bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥17.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥16.2bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥14.7bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥9.6bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥18.7bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥17.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥209.1bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥206.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥195.5bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥191.8bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥168.7bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥40.1bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥43.9bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥169.0bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥163.0bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥149.9bn | at 2022-03-31d | Cons. | Net assets |
| Net assets / equity | ¥138.0bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥124.4bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥60.2bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥68.0bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥57.2bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥64.9bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥61.0bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥53.6bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥46.1bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥23.9bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥23.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥23.1bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥21.7bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥20.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥14.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥14.2bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥10.8bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥11.3bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥14.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥17.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥4.8bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥3.0bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥3.7bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥622.44 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥571.25 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥536.19 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥486.67 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥316.52 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥5,863.22 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥5,390.09 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,954.7 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,562.94 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,114.98 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 80.8% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.8% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 76.7% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 72.0% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.7% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 11.3% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 11.0% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 11.3% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 11.2% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.9% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 3,443 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 3,382 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 3,348 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 3,291 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 3,208 | at 2020-03-31d | Cons. | Number of employees |
| Revenue | ¥87.0bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥82.3bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥82.5bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥81.8bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥71.8bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥14.5bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥12.4bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥21.2bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥18.5bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥18.0bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥15.0bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥9.9bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥21.4bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥18.7bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥17.1bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥14.8bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥14.4bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥12.0bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥8.0bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥177.6bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥176.0bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥163.5bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥158.1bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥137.3bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥46.9bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥48.8bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥130.7bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥127.2bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥117.1bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥107.2bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥96.7bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥37.9bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥46.1bn | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥567.96 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥489.27 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥477.6 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥397.01 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥264.8 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥185 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥240 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥305 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥275 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥180 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥4,534.7 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥4,204.87 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,871.21 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,543.95 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,199.28 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 73.6% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 72.3% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 71.6% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 67.8% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.4% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 13.2% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.1% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.9% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 11.8% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.5% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 37,747,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 39,176,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 19,588,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 19,588,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 19,588,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 699 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 690 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 669 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 659 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 651 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 64
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥97.2bn |
| Consumables And Other Productsreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥1.6bn |
| Consumables And Other Productsreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥757m |
| Consumables And Other Productsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥40.2bn |
| Consumables And Other Productsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥40.2bn |
| Consumables And Other Productsreportable segment | segment assets | at 2024-03-31 | ¥27.3bn |
| Consumables And Other Productsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥6.9bn |
| Medical Treatment Equipmentreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥11.7bn |
| Medical Treatment Equipmentreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥8.2bn |
| Medical Treatment Equipmentreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥59.7bn |
| Medical Treatment Equipmentreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥59.7bn |
| Medical Treatment Equipmentreportable segment | segment assets | at 2024-03-31 | ¥56.0bn |
| Medical Treatment Equipmentreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥12.8bn |
| Patient Monitoring Equipmentreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥384m |
| Patient Monitoring Equipmentreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥182m |
| Patient Monitoring Equipmentreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥9.7bn |
| Patient Monitoring Equipmentreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥9.7bn |
| Patient Monitoring Equipmentreportable segment | segment assets | at 2024-03-31 | ¥7.6bn |
| Patient Monitoring Equipmentreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥1.7bn |
| Physiological Diagnostic Equipmentreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥1.2bn |
| Physiological Diagnostic Equipmentreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥577m |
| Physiological Diagnostic Equipmentreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥30.7bn |
| Physiological Diagnostic Equipmentreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥30.7bn |
| Physiological Diagnostic Equipmentreportable segment | segment assets | at 2024-03-31 | ¥21.1bn |
| Physiological Diagnostic Equipmentreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥5.1bn |
| —segment total | employees | at 2024-03-31 | 2740 pure |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥14.9bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥9.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥140.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥140.3bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥111.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥26.5bn |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥100.1bn |
| Consumables And Other Productsreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥1.3bn |
| Consumables And Other Productsreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥699m |
| Consumables And Other Productsreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥36.5bn |
| Consumables And Other Productsreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥36.5bn |
| Consumables And Other Productsreportable segment | segment assets | at 2023-03-31 | ¥25.7bn |
| Consumables And Other Productsreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥4.7bn |
| Medical Treatment Equipmentreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥8.3bn |
| Medical Treatment Equipmentreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥7.9bn |
| Medical Treatment Equipmentreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥55.4bn |
| Medical Treatment Equipmentreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥55.4bn |
| Medical Treatment Equipmentreportable segment | segment assets | at 2023-03-31 | ¥50.7bn |
| Medical Treatment Equipmentreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥12.4bn |
| Patient Monitoring Equipmentreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥417m |
| Patient Monitoring Equipmentreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥222m |
| Patient Monitoring Equipmentreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥11.6bn |
| Patient Monitoring Equipmentreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥11.6bn |
| Patient Monitoring Equipmentreportable segment | segment assets | at 2023-03-31 | ¥8.7bn |
| Patient Monitoring Equipmentreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥2.1bn |
| Physiological Diagnostic Equipmentreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥1.1bn |
| Physiological Diagnostic Equipmentreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥594m |
| Physiological Diagnostic Equipmentreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥31.1bn |
| Physiological Diagnostic Equipmentreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥31.1bn |
| Physiological Diagnostic Equipmentreportable segment | segment assets | at 2023-03-31 | ¥21.7bn |
| Physiological Diagnostic Equipmentreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥4.9bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-04-01 → 2023-03-31 | ¥11.1bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥9.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥134.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥134.6bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥106.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥24.1bn |
| —segment total | employees | at 2024-03-31 | 591 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,684
| Item | Context | Value | Unit |
|---|---|---|---|
| Purchase of treasury stock fin cf | Prior1YearDuration | -93000000 | JPY |
| Purchase of treasury stock fin cf | CurrentYearDuration | -11258000000 | JPY |
| Proceeds from sales of treasury stock fin cf | Prior1YearDuration | 102000000 | JPY |
| Proceeds from sales of treasury stock fin cf | CurrentYearDuration | 10000000 | JPY |
| Cash dividends paid fin cf | Prior1YearDuration | -5253000000 | JPY |
| Cash dividends paid fin cf | CurrentYearDuration | -5492000000 | JPY |
| Repayments of lease obligations fin cf | Prior1YearDuration | -306000000 | JPY |
| Repayments of lease obligations fin cf | CurrentYearDuration | -325000000 | JPY |
| Net cash provided by used in financing activities | Prior1YearDuration | -5551000000 | JPY |
| Net cash provided by used in financing activities | CurrentYearDuration | -17066000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YearDuration | 391000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYearDuration | 190000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YearDuration | 3768000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYearDuration | -7741000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 61030000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 64939000000 | JPY |
| Increase in cash and cash equivalents resulting from merger with unconsolidated subsidiaries cce | Prior1YearDuration | 140000000 | JPY |
| Increase in cash and cash equivalents resulting from merger with unconsolidated subsidiaries cce | CurrentYearDuration | － | JPY |
| Cash and cash equivalents | Prior1YearInstant | 64939000000 | JPY |
| Cash and cash equivalents | CurrentYearInstant | 57198000000 | JPY |
| Number of consolidated subsidiaries | CurrentYearInstant | 48 | |
| Write downs of inventories | Prior1YearDuration | 597000000 | JPY |
| Write downs of inventories | CurrentYearDuration | 1214000000 | JPY |
| Directors compensations salaries and allowances sga | Prior1YearDuration | 17247000000 | JPY |
| Directors compensations salaries and allowances sga | CurrentYearDuration | 17729000000 | JPY |
| Provision for bonuses sga | Prior1YearDuration | 5747000000 | JPY |
| Provision for bonuses sga | CurrentYearDuration | 5254000000 | JPY |
| Provision for directors bonuses sga | Prior1YearDuration | 465000000 | JPY |
| Provision for directors bonuses sga | CurrentYearDuration | 531000000 | JPY |
| Provision for directors retirement benefits sga | Prior1YearDuration | 50000000 | JPY |
| Provision for directors retirement benefits sga | CurrentYearDuration | 41000000 | JPY |
| Provision for share based remuneration for directors and other officers sga | Prior1YearDuration | 57000000 | JPY |
| Provision for share based remuneration for directors and other officers sga | CurrentYearDuration | 35000000 | JPY |
| Provision of allowance for doubtful accounts sga | Prior1YearDuration | 3000000 | JPY |
| Provision of allowance for doubtful accounts sga | CurrentYearDuration | 33000000 | JPY |
| Retirement benefit expenses sga | Prior1YearDuration | 1229000000 | JPY |
| Retirement benefit expenses sga | CurrentYearDuration | 1080000000 | JPY |
| Depreciation sga | Prior1YearDuration | 1812000000 | JPY |
| Depreciation sga | CurrentYearDuration | 1717000000 | JPY |
| Research and development expenses sga | Prior1YearDuration | 3785000000 | JPY |
| Research and development expenses sga | CurrentYearDuration | 4740000000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E02304-000PhysiologicalDiagnosticEquipmentReportableSegmentsMember | 31058000000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E02304-000PatientMonitoringEquipmentReportableSegmentsMember | 11625000000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E02304-000MedicalTreatmentEquipmentReportableSegmentsMember | 55442000000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E02304-000ConsumablesAndOtherProductsReportableSegmentsMember | 36522000000 | JPY |
| Revenues from external customers | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 134648000000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YearDuration | 134648000000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E02304-000PhysiologicalDiagnosticEquipmentReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E02304-000PatientMonitoringEquipmentReportableSegmentsMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |